VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Inclusion Criteria:

1. Age ≥18 years of age at the time of signing the informed consent.

2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-relatedco-morbid condition (treated or untreated), and BMI <50 kg/m2

• Weight-related co-morbid conditions include hypertension, dyslipidemia,obstructive sleep apnea or cardiovascular disease.

• BMI calculated at the Screening visit will be used to determine eligibility.

Exclusion Criteria:

1. History of or current clinically significant medical or psychiatric disorder that,in the opinion of the Investigator, does not support study participation

2. Self-reported body weight change of 5% or more within 3 months of screening

3. Current or past diagnosis of diabetes mellitus (including type 1, type 2,gestational)

4. Current or past diagnosis of chronic pancreatitis

5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals withelevated calcitonin at initial screening may be re-screened)

6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening

7. Any prescription or over-the-counter medications intended for weight loss within 6months of screening